Regeneron Faces Legal, Clinical, and Market Storm Ahead of Earnings
Regeneron faces class‑action lawsuits, a failed Phase III trial, and a sharp stock drop, with investors eye upcoming earnings to gauge whether the biotech giant can recover.
3 minutes to read